Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Apr 22;115(16):3206-14.
doi: 10.1182/blood-2009-10-248146. Epub 2010 Feb 12.
Claus R Bartram, Maria Grazia Valsecchi, André Schrauder, Renate Panzer-Grümayer, Anja Möricke, Maurizio Aricò, Martin Zimmermann, Georg Mann, Giulio De Rossi, Martin Stanulla, Franco Locatelli, Giuseppe Basso, Felix Niggli, Elena Barisone, Günter Henze, Wolf-Dieter Ludwig, Oskar A Haas, Giovanni Cazzaniga, Rolf Koehler, Daniela Silvestri, Jutta Bradtke, Rosanna Parasole, Rita Beier, Jacques J M van Dongen, Andrea Biondi, Martin Schrappe
Affiliations
- PMID: 20154213
- DOI: 10.1182/blood-2009-10-248146
Free article
Randomized Controlled Trial
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter et al. Blood. 2010.
Free article
Abstract
The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10(-4)); MRD high risk (MRD-HR) if 10(-3) or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP.
Comment in
- Minimal residual disease in all.
Richards L. Richards L. Nat Rev Clin Oncol. 2010 Jul;7(7):356. doi: 10.1038/nrclinonc.2010.95. Nat Rev Clin Oncol. 2010. PMID: 20614558 No abstract available.
Similar articles
- Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
Ronceray L, Dworzak M, Dieckmann K, Ebetsberger-Dachs G, Glogova E, Haas OA, Jones N, Nebral K, Moser R, Lion T, Meister B, Panzer-Grümayer R, Strehl S, Peters C, Pötschger U, Urban C, Mann G, Attarbaschi A; Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Ronceray L, et al. Wien Klin Wochenschr. 2024 Jul;136(13-14):405-418. doi: 10.1007/s00508-023-02249-6. Epub 2023 Aug 3. Wien Klin Wochenschr. 2024. PMID: 37535134 - Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A, Parasole R, Zimmermann M, Dworzak M, Buldini B, Reiter A, Basso G, Klingebiel T, Messina C, Ratei R, Cazzaniga G, Koehler R, Locatelli F, Schäfer BW, Aricò M, Welte K, van Dongen JJ, Gadner H, Biondi A, Conter V. Schrappe M, et al. Blood. 2011 Aug 25;118(8):2077-84. doi: 10.1182/blood-2011-03-338707. Epub 2011 Jun 30. Blood. 2011. PMID: 21719599 Clinical Trial. - Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M. Möricke A, et al. Blood. 2016 Apr 28;127(17):2101-12. doi: 10.1182/blood-2015-09-670729. Epub 2016 Feb 17. Blood. 2016. PMID: 26888258 Clinical Trial. - Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT. Tzortzatou-Stathopoulou F, et al. J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review. - Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.
Health Quality Ontario. Health Quality Ontario. Ont Health Technol Assess Ser. 2016 Mar 8;16(7):1-52. eCollection 2016. Ont Health Technol Assess Ser. 2016. PMID: 27099643 Free PMC article. Review.
Cited by
- Association of CDKN2A/2B deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia.
Onizuka M, Kikkawa E, Machida S, Toyosaki M, Suzuki R, Ogiya D, Aoyama Y, Amaki J, Harada K, Hara R, Shiraiwa S, Ogawa Y, Kawada H, Ando K. Onizuka M, et al. Blood Cell Ther. 2023 Jul 21;6(3):80-86. doi: 10.31547/bct-2023-004. eCollection 2023 Aug 25. Blood Cell Ther. 2023. PMID: 38146355 Free PMC article. - Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M, Schieck M, Hofmann W, Tauscher M, Lentes J, Bergmann A, Stelter M, Möricke A, Alten J, Schlegelberger B, Schrappe M, Zimmermann M, Stanulla M, Cario G, Steinemann D. Jung M, et al. Genes Chromosomes Cancer. 2020 Nov;59(11):667-671. doi: 10.1002/gcc.22882. Epub 2020 Jul 7. Genes Chromosomes Cancer. 2020. PMID: 32592278 Free PMC article. - Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Burns MA, et al. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. doi: 10.1002/pbc.28719. Epub 2020 Oct 7. Pediatr Blood Cancer. 2021. PMID: 33026184 Free PMC article. - Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G. Zuna J, et al. Leukemia. 2022 Dec;36(12):2793-2801. doi: 10.1038/s41375-022-01668-0. Epub 2022 Aug 6. Leukemia. 2022. PMID: 35933523 - [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
Lan Y, Chen XJ, Zou Y, Ruan M, Zhu XF. Lan Y, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2019 May;21(5):405-410. doi: 10.7499/j.issn.1008-8830.2019.05.001. Zhongguo Dang Dai Er Ke Za Zhi. 2019. PMID: 31104652 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials